No. I'll go another route. Thank you very much.
General Bilodeau, this is for you. Somalia came up in conversation tonight, and this committee did meet with individuals who experienced the challenges of being administered mefloquine while they were there. We did another major study on that issue.
I was thinking about it. We've had no feedback from women in the military, and this drug has been used right up through Afghanistan and is now a drug of last resort. However, it was made clear in the report that this did not impact civilian use. I lost a friend who was a considerable and amazing veterans' advocate, who had taken it with her husband on a trip to Thailand. She eventually did take her own life.
Every other country—U.K., Germany, Ireland, Australia and the U.S.—has identified this as a concern, as a brain stem injury, and is treating specifically for that, yet we do not have that in Canada. There is no recognition of the results of that particular drug. I know part of the inquiry was to do with a number of other things, but then the inquiry was shut down before mefloquine was approached.
Are you aware of women who were administered mefloquine when serving, and is there any feedback at all as to its impact on them?